Skip to main content

Advertisement

Table 2 Baseline characteristics with/without statin therapy for patients allocated to rivaroxaban and placebo (shown separately)

From: Influence of statin use on the incidence of recurrent venous thromboembolism and major bleeding in patients receiving rivaroxaban or standard anticoagulant therapy

  Rivaroxaban p-value Placebo p-value
  Patients treated with statins (n=113) Patients not treated with statins (n=485)   Patients treated with statins (n=117) Patients not treated with statins (n=473)  
Mean age, years 64.3 56.7 <0.01 66.9 56.3 <0.01
Men, n (%) 62 (54.9) 289 (59.6) 0.36 66 (56.4) 272 (57.5) 0.42
Mean BMI, kg/m2 29.9 28.1 <0.01 29.8 28.0 <0.01
Creatinine clearance, n (%)    0.20    <0.01
    <50 ml/min 10 (8.8) 31 (6.4)   17 (14.5) 33 (7.0)  
    50–<80 ml/min 33 (29.2) 113 (23.3)   39 (33.3) 96 (20.3)  
    ≥80 ml/min 68 (60.2) 335 (69.1)   60 (51.3) 340 (71.9)  
    Missing 2 (1.8) 6 (1.2)   1 (0.9) 4 (0.8)  
Planned treatment duration, n (%)    0.14    0.19
    6 months 61 (54.0) 298 (61.4)   68 (58.1) 285 (60.3)  
    12 months 52 (46.0) 187 (38.6)   49 (41.9) 188 (39.7)  
Index event, n (%)    <0.01    <0.01
    Only DVT 48 (42.5) 325 (67.0)   54 (46.2) 292 (61.7)  
    PE ± DVT 61 (54.0) 151 (31.1)   61 (52.1) 172 (36.4)  
    Index event not confirmed 4 (3.5) 9 (1.9)   2 (1.7) 9 (1.9)  
Immobilization at randomization, n (%) 17 (15.0) 72 (14.8) 0.96 17 (14.5) 59 (12.5) 0.66
Active cancer at randomization, n (%) 5 (4.4) 23 (4.7) 0.89 6 (5.1) 20 (4.2) 0.85
Ischemic heart disease, n (%) 19 (16.8) 14 (2.9) <0.01 40 (34.2) 20 (4.2) <0.01
Peripheral arterial disease, n (%) 1 (0.9) 2 (0.4)   1 (0.9) 0  
Ischemic cerebrovascular disease, n (%) 0 4 (0.8)   2 (1.7) 5 (1.1)  
ASA use at baseline, n (%) 5 (4.4) 15 (3.1) <0.01 29 (24.8) 18 (3.8) <0.01
ASA stopped at randomization, n 0 3   0 0  
Hypertension, n (%) 80 (70.8) 161 (33.2) <0.01 73 (62.4) 154 (32.6) <0.01
Diabetes, n (%) 30 (26.5) 28 (5.8) <0.01 35 (29.9) 21 (4.4) <0.01
  1. ASA, acetylsalicylic acid; BMI, body mass index; DVT, deep vein thrombosis; PE, pulmonary embolism.
  2. Data from EINSTEIN Extension, safety population.